BioPharma Dive October 27, 2024
The startup, which is backed by Novo Holdings and a handful of other venture firms, is the latest to capitalize on interest in the targeted cancer drugs.
Dive Brief:
- Kivu Biosciences, a San Francisco-based biotechnology startup developing targeted drugs for cancer, has raised $92 million in a Series A round, the company said Monday.
- Kivu will use the funds to advance technology it claims can help address some of the current limitations of antibody-drug conjugates, or ADCs. Its technology, Kivu says, can yield ADCs that are more precise and stable when traveling to their targets in the body, which should reduce the risk of side effects. Kivu plans to start its first clinical trial in solid tumors next year. ...
Today's Sponsors
Today's Sponsor